Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience

IntroductionImmunotherapy with nivolumab (a monoclonal antibody that targets the programmed cell death protein 1, PD1) has become the standard treatment for patients with metastatic renal cell carcinoma (mRCC) after progression to single-agent tyrosine kinase inhibitors. However, the optimal duratio...

Full description

Bibliographic Details
Main Authors: Davide Bimbatti, Michele Dionese, Eleonora Lai, Nicolò Cavasin, Umberto Basso, Alvise Mattana, Francesco Pierantoni, Vittorina Zagonel, Marco Maruzzo
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
mRCC
renal cell carcinoma
anti-PD1
immunotherapy
rechallenge
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.960751/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.960751/full

Similar Items